文献速递临床试验与 GCP流行病学与生物统计

留置胸膜导管与滑石粉胸膜固定术对恶性胸腔积液住院天数的影响:AMPLE随机临床试验

Effect of an Indwelling Pleural Catheter vs Talc Pleurodesis on Hospitalization Days in Patients With Malignant Pleural Effusion: The AMPLE Randomized Clinical Trial.
PubMed 文献 · JAMA · 2017-01-01

这项开放标签随机临床试验在澳大利亚、新西兰、新加坡和香港的9个中心纳入146例有症状的恶性胸腔积液患者,按1:1随机分为留置胸膜导管组(74例)和滑石粉胸膜固定术组(72例)。主要终点是从操作到死亡或12个月内的总住院天数,留置胸膜导管组显著少于胸膜固定术组(中位数10.0天 vs 12.0天,P=.03)。作者认为住院天数差异的临床重要性尚不确定,这些发现可能有助于患者选择胸腔积液的管理方式。

要点

  • 留置胸膜导管组总住院天数中位数10.0天,少于滑石粉胸膜固定术组的12.0天(P=.03)。
  • 住院天数的减少主要来自积液相关住院天数(中位数1.0天 vs 4.0天,P<.001)。
  • 留置胸膜导管组需要进一步同侧有创胸膜引流的患者比例低于胸膜固定术组(4.1% vs 22.5%)。

核心结论

  • 在恶性胸腔积液患者中,与滑石粉胸膜固定术相比,留置胸膜导管治疗使从治疗到死亡期间的住院天数更少,但差异幅度的临床重要性尚不确定。
  • 这些发现可能有助于患者选择胸腔积液的管理方式。

研究设计与样本

  • 开放标签随机临床试验,2012年7月至2014年10月从澳大利亚、新西兰、新加坡和香港的9个中心招募参与者,随访12个月(研究结束日期:2015年10月16日)。
  • 纳入146例有症状的恶性胸腔积液患者,均未接受过留置胸膜导管或胸膜固定术治疗。
  • 按1:1随机分为留置胸膜导管组(74例)和滑石粉胸膜固定术组(72例),按恶性肿瘤类型(间皮瘤 vs 其他)和陷闭肺(是 vs 否)进行最小化,并按地区(澳大利亚 vs 亚洲)分层。
  • 146例随机患者中位年龄70.5岁,男性占56.2%;2例在接受的随机干预前退出并被排除。

主要发现

  • 留置胸膜导管组住院天数显著少于胸膜固定术组(中位数10.0天[四分位距3-17] vs 12.0天[四分位距7-21];P=.03;Hodges-Lehmann差值估计2.92天;95%CI 0.43-5.84)。
  • 住院天数的减少主要来自积液相关住院天数(留置胸膜导管组中位数1.0天[四分位距1-3] vs 胸膜固定术组4.0天[四分位距3-6];P<.001;Hodges-Lehmann估计2.06天;95%CI 1.53-2.58)。
  • 随机分配至留置胸膜导管组需要进一步同侧有创胸膜引流的患者更少(4.1% vs 22.5%;差值18.4%;95%CI 7.7%-29.2%)。
  • 留置胸膜导管或滑石粉胸膜固定术在呼吸困难改善或生活质量方面无显著差异。
  • 留置胸膜导管组22例患者发生不良事件(30起),胸膜固定术组13例患者发生不良事件(18起)。

关键数值与推荐

  • 主要终点为从操作到死亡或至12个月的总住院天数:留置胸膜导管组中位数10.0天(四分位距3-17) vs 滑石粉胸膜固定术组12.0天(四分位距7-21),P=.03。
  • 积液相关住院天数:留置胸膜导管组中位数1.0天(四分位距1-3) vs 胸膜固定术组4.0天(四分位距3-6),P<.001。
  • 进一步同侧有创胸膜引流比例:留置胸膜导管组4.1% vs 胸膜固定术组22.5%,差值18.4%(95%CI 7.7%-29.2%)。

临床怎么用

  • 原文结论未给出具体推荐,仅指出这些发现可能有助于患者选择胸腔积液的管理方式,并认为住院天数差异幅度的临床重要性尚不确定。

局限性

  • 作者指出留置胸膜导管与滑石粉胸膜固定术之间住院天数差异幅度的临床重要性尚不确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Indwelling pleural catheter and talc pleurodesis are established treatments for malignant pleural effusions among patients with poor prognosis. OBJECTIVE: To determine whether indwelling pleural catheters are more effective than talc pleurodesis in reducing total hospitalization days in the remaining lifespan of patients with malignant pleural effusion. DESIGN, SETTING, AND PARTICIPANTS: This open-label, randomized clinical trial included participants recruited from 9 centers in Australia, New Zealand, Singapore, and Hong Kong between July 2012 and October 2014; they were followed up for 12 months (study end date: October 16, 2015). Patients (n = 146) with symptomatic malignant pleural effusion who had not undergone indwelling pleural catheter or pleurodesis treatment were included. INTERVENTIONS: Participants were randomized (1:1) to indwelling pleural catheter (n = 74) or talc pleurodesis (n = 72), minimized by malignancy (mesothelioma vs others) and trapped lung (vs not), and stratified by region (Australia vs Asia). MAIN OUTCOMES AND MEASURES: The primary end point was the total number of days spent in hospital from procedure to death or to 12 months. Secondary outcomes included further pleural interventions, patient-reported breathlessness, quality-of-life measures, and adverse events. RESULTS: Among the 146 patients who were randomized (median age, 70.5 years; 56.2% male), 2 withdrew before receiving the randomized intervention and were excluded. The indwelling pleural catheter group spent significantly fewer days in hospital than the pleurodesis group (median, 10.0 [interquartile range [IQR], 3-17] vs 12.0 [IQR, 7-21] days; P = .03; Hodges-Lehmann estimate of difference, 2.92 days; 95% CI, 0.43-5.84). The reduction was mainly in effusion-related hospitalization days (median, 1.0 [IQR, 1-3] day with the indwelling pleural catheter vs 4.0 (IQR, 3-6) days with pleurodesis; P < .001; Hodges-Lehmann estimate, 2.06 days; 95% CI, 1.53-2.58). Fewer patients randomized to indwelling pleural catheter required further ipsilateral invasive pleural drainages (4.1% vs 22.5%; difference, 18.4%; 95% CI, 7.7%-29.2%). There were no significant differences in improvements in breathlessness or quality of life offered by indwelling pleural catheter or talc pleurodesis. Adverse events were seen in 22 patients in the indwelling pleural catheter group (30 events) and 13 patients in the pleurodesis group (18 events). CONCLUSIONS AND RELEVANCE: Among patients with malignant pleural effusion, treatment with an indwelling pleural catheter vs talc pleurodesis resulted in fewer hospitalization days from treatment to death, but the magnitude of the difference is of uncertain clinical importance. These findings may help inform patient choice of management for pleural effusion. TRIAL REGISTRATION: anzctr.org.au Identifier: ACTRN12611000567921.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Thomas R, Fysh ETH, Smith NA, et al. Effect of an Indwelling Pleural Catheter vs Talc Pleurodesis on Hospitalization Days in Patients With Malignant Pleural Effusion: The AMPLE Randomized Clinical Trial. JAMA. 2017. PMID: 29164255. doi:10.1001/jama.2017.17426

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。